| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| Expenses incurred | 91 | |||
| Less- government grants | 0 | |||
| Research and development expenses, net | 91 | |||
| Marketing expenses | 1 | |||
| General and administrative expenses | 194 | |||
| Total operating loss | -286 | |||
| Financial expenses, net | -415 | |||
| Loss for the period | -701 | |||
| Basic loss per common stock | -0.01 | |||
| Dilutive loss per common stock | -0.01 | |||
| Weighted average number of common stock, basic | 73,755,083 | |||
| Weighted average number of common stock, diluted | 73,755,083 | |||
IR-Med, Inc. (IRME)
IR-Med, Inc. (IRME)